Which statement is true regarding acamprosate and renal impairment?

Which statement is true regarding acamprosate and renal impairment?

• A. It Is Contraindicated In Renal Impairment
• B. It Is Contraindicated In Hepatic Impairment
• C. It Is Safe In Renal Impairment With No Dose Adjustment
• D. It Is Contraindicated In Pregnancy

Answer: (A)

Acamprosate is eliminated primarily by the kidneys, so how well the kidneys work directly determines how much drug stays in the body. When renal function is reduced, drug exposure increases. Because this can lead to toxicity, acamprosate should not be used in severe renal impairment. In milder renal impairment, the dose is adjusted to reduce exposure, rather than avoiding the drug altogether. Hepatic impairment does not usually necessitate avoiding acamprosate, since it is not heavily dependent on liver metabolism. Pregnancy safety data exist but do not make it a universal contraindication. Given these points, the statement that it is contraindicated in renal impairment reflects the safety concern with severe renal dysfunction due to impaired clearance.

Acamprosate is eliminated primarily by the kidneys, so how well the kidneys work directly determines how much drug stays in the body.

When renal function is reduced, drug exposure increases. Because this can lead to toxicity, acamprosate should not be used in severe renal impairment. In milder renal impairment, the dose is adjusted to reduce exposure, rather than avoiding the drug altogether. Hepatic impairment does not usually necessitate avoiding acamprosate, since it is not heavily dependent on liver metabolism. Pregnancy safety data exist but do not make it a universal contraindication.

Given these points, the statement that it is contraindicated in renal impairment reflects the safety concern with severe renal dysfunction due to impaired clearance.